195 related articles for article (PubMed ID: 16079315)
1. Detection of micrometastatic disease in bone marrow: is it ready for prime time?
Janni W; Rack B; Lindemann K; Harbeck N
Oncologist; 2005 Aug; 10(7):480-92. PubMed ID: 16079315
[TBL] [Abstract][Full Text] [Related]
2. DTCs in breast cancer: clinical research and practice.
Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences.
Köstler WJ; Brodowicz T; Hejna M; Wiltschke C; Zielinski CC
Cancer Detect Prev; 2000; 24(4):376-403. PubMed ID: 11059569
[TBL] [Abstract][Full Text] [Related]
4. [Minimal residual disease in solid cancer. Prognostic value and therapeutic consequences].
Allgayer H; Heiss MM
Fortschr Med Orig; 2001; 119(1):1-4. PubMed ID: 11935652
[TBL] [Abstract][Full Text] [Related]
5. [Significance of minimal residual disease for the estimation of the prognosis and for therapeutic decisions in solid tumors].
Hinterberger W; Buxhofer V; Ogris E; Zelenka P; Kier P; Ruckser R; Dorner S; Habertheuer KH; Vedovelli H; Schindler S; Hinterberger-Fischer M
Acta Med Austriaca Suppl; 2002; 59():2-8. PubMed ID: 12506753
[TBL] [Abstract][Full Text] [Related]
6. [Minimal Residual Disease (MRD) in gastric carcinoma--an overview].
Garlipp B; Steinert R; Lippert H; Meyer F
Z Gastroenterol; 2011 Feb; 49(2):225-33. PubMed ID: 21298608
[TBL] [Abstract][Full Text] [Related]
7. [Minimal residual disease in gastrointestinal tumors: tumor detection in bone marrow, blood and lymph nodes].
Rosenberg R; Nekarda H; Thorban S; Siewert JR
Acta Med Austriaca Suppl; 2002; 59():42-53. PubMed ID: 12506760
[TBL] [Abstract][Full Text] [Related]
8. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
9. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.
Becker S; Becker-Pergola G; Wallwiener D; Solomayer EF; Fehm T
Breast Cancer Res Treat; 2006 May; 97(1):91-6. PubMed ID: 16319975
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual marrow disease: detection and significance of isolated tumour cells in bone marrow.
Iorgulescu DG; Kiroff GK
ANZ J Surg; 2001 Jun; 71(6):365-76. PubMed ID: 11409023
[TBL] [Abstract][Full Text] [Related]
11. [Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
Ditsch N; Funke I; Mayer B; Untch M
MMW Fortschr Med; 2002 Oct; 144(41):37-9. PubMed ID: 12474359
[TBL] [Abstract][Full Text] [Related]
12. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.
Riethdorf S; Pantel K
Pathobiology; 2008; 75(2):140-8. PubMed ID: 18544969
[TBL] [Abstract][Full Text] [Related]
13. Hematogenous micrometastases in osteosarcoma patients.
Bruland OS; Høifødt H; Saeter G; Smeland S; Fodstad O
Clin Cancer Res; 2005 Jul; 11(13):4666-73. PubMed ID: 16000559
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the detection of bone marrow micrometastases: A promising area for research or just another false hope? A review of the literature.
Athanassiadou P; Grapsa D
Cancer Metastasis Rev; 2006 Dec; 25(4):507-19. PubMed ID: 17160555
[TBL] [Abstract][Full Text] [Related]
15. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA.
Janku F; Srovnal J; Korinkova G; Novotny J; Petruzelka L; Power D; Matous B; Hajduch M
Neoplasma; 2008; 55(4):317-22. PubMed ID: 18505343
[TBL] [Abstract][Full Text] [Related]
16. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
17. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
18. Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer.
Bjørnland K; Flatmark K; Mala T; Mathisen O; Bakka A; Aasen AO; Bergan A; Søreide O; Fodstad O
J Surg Oncol; 2003 Apr; 82(4):224-7. PubMed ID: 12672004
[TBL] [Abstract][Full Text] [Related]
19. [Micrometastases in pediatric oncology].
Bernard F; Aerts I; Margueritte G; Astruc J
Bull Cancer; 2001 Jun; 88(6):577-80. PubMed ID: 11459704
[TBL] [Abstract][Full Text] [Related]
20. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
